Warfarin sodium is a vitamin K antagonist that is plagued by large variability in patient response, including higher dose requirements among African Americans. Polymorphisms in the gene encoding apolipoprotein E (APOE) may partly explain this variability by altering transport of vitamin K to the liver. In a prospective cohort study of 232 individuals (52.2% Caucasian and 47.8% African American) initiating warfarin therapy, the weekly maintenance dose was significantly higher for African Americans than for Caucasians (mean 42.9 versus mean 36.9 mg, P ¼ 0.018), and the e4 allele was more common among African Americans (37.8 versus 26.4% for Caucasians). In multivariable analyses, the presence of the e4 allele was associated with a statistically significantly higher warfarin dose among African Americans (median 45.0 mg in e4 carriers versus 35.0 mg in non-e4 carriers, P ¼ 0.014) but not Caucasians (38.1 versus 35.0 mg, P ¼ 0.60). In addition, warfarin maintenance dose increased among African Americans according to genotype previously associated with differential hepatic chylomicron clearance (e2/e2 or e2/e3: 30.0 mg; e3/e3: 35.0 mg; e3/e4 or e4/e4: 45.0 mg; P ¼ 0.012), although the e4/e4 genotype was rare and not clearly associated with higher doses. The association of APOE with warfarin dosing was independent of CYP2C9 and VKORC1 polymorphisms. APOE polymorphisms thus may be important determinants of warfarin maintenance dose and could explain at least some of the observed racial differences in dose requirements.
Introduction
Warfarin sodium is the mainstay of oral anticoagulation therapy in the US and many other countries. When dosed properly it is a highly efficacious drug for maintaining sufficient, but not excessive, levels of anticoagulation. However, there is large interindividual variability in warfarin dose requirements. 1 In addition, African Americans have been noted to require higher doses of warfarin than Caucasians. 2, 3 The above observations have led to investigations aimed at identifying functional genetic variants that alter the response to warfarin. Two such sets of variants within the cytochrome P-450 CYP2C9 enzyme and the vitamin K epoxide reductase complex 1 (VKORC1) have been clearly associated with a lower warfarin maintenance dose requirement. 4, 5 The genotypes that are associated with these lower dose requirements are relatively common in Caucasians but rare in African Americans. 2, 3 Thus, one possible explanation for higher dose requirements in African Americans is the relative rarity of these variants. Another possible explanation is the presence of other functional genetic variants in African Americans.
One such possible source of variability in individual and race-specific warfarin responses is the lipoprotein, apolipoprotein E (APOE). Because warfarin affects coagulation by inhibiting the regeneration of reduced vitamin K from oxidized vitamin K in the liver, the availability of hepatic vitamin K is likely to alter the dose requirement of warfarin. 6 The main circulating form of vitamin K, phylloquinone, is bound to chylomicrons and chylomicron remnants within the plasma, and APOE influences chylomicron remnant uptake by the liver. 7 There are three common variants of the APOE gene (designated e2, e3 and e4) that encode the three common isoforms of the APOE molecule; their prevalence varies by race, with e4 being more common in African Americans than in Caucasians. 8 Each isoform varies in its ability to facilitate clearance of vitamin-K-rich lipoproteins from plasma, with e4 having the greatest clearance. [9] [10] [11] [12] Plasma vitamin K levels also vary by APOE genotype, with the highest levels among e2 allele carriers and the lowest in e4 carriers. [10] [11] [12] Accordingly, some investigators have proposed that the lower plasma levels of vitamin K in e4 carriers lead to lower anticoagulant requirements, 13 whereas others have suggested that the greater uptake of vitamin K into the liver leads to increased availability of vitamin K for coagulation proteins and thus a higher anticoagulant drug requirement to achieve adequate anticoagulation in e4 carriers. 14 To date, observational studies of the effect of APOE genotype on anticoagulant requirements have produced contrasting results. [13] [14] [15] [16] The INR Adherence and Genetics (IN-RANGE) study is a prospective cohort study with a primary aim of examining the relationship between APOE genotype and warfarin response. The study also sought to determine the effect of APOE polymorphisms in African Americans, a group not yet studied, independent of the effects of CYP2C9 and VKORC1 variants.
Results

Patient population and distribution of genotypes
The study cohort comprised 232 patients (mean age 58.8714.9 years) of whom 121 (52.2%) were self-reported Caucasian and 111 (47.8%) were self-reported African American. The clinical characteristics of the cohort by APOE genotype are shown in Table 1 and the distribution of APOE genotypes within the Caucasian and African American subgroups is shown in Table 2 . The allele frequencies for e2, e3 and e4 were, respectively, 7.9, 78.5 and 13.6% in Caucasians and 12.6, 66.2 and 21.1% in African Americans. As expected, the APOE e4 variant was more common in African Americans. The allele distribution was in HardyWeinberg equilibrium for both groups (P40.25). Patients with the APOE e4 variant also were more likely to use more medications that potentiate the effect of warfarin ( Table 1 ). The prevalence of APOE variants was the same among those who reached maintenance dose (APOE e2, e3 and e4 variants: 10, 73 and 17%) versus those who did not (APOE e2, e3 and e4 variants: 10, 72 and 18%).
Effect of APOE genotype on maintenance dose of warfarin In the entire cohort, e4 carriers had a significantly higher median weekly maintenance dose (44.4 mg) than noncarriers (35.0 mg; P ¼ 0.0043). Those with the e2/e2 and e2/e3 genotypes had the lowest median maintenance dose (31.2 mg), e3/e3 homozygotes had an intermediate maintenance dose (35.0 mg) and those with the e4/e3 or e4/e4 genotypes had the highest maintenance dose (45.0 mg); these differences were statistically significant (P ¼ 0.0118). As explained under Materials and methods, the 10 e2/e4 patients were excluded a priori from the analysis of the threelevel variable. These 10 patients had a median weekly maintenance dose of 35.0 mg, the same as that of the e3/e3 homozygotes. Adjusted for age; sex; race; insurance status; study site; CYP2C9 genotype; VKORC1 genotype, history of prior warfarin use; medications that interact with warfarin; employment; marital status; body mass index; indication for warfarin; smoking; maximum number of drinks of alcohol consumed on any one occasion; and history of arrhythmias, myocardial infarction, other heart disease, stroke, pulmonary embolism, deep vein thrombosis, hyperthyroidism, cancer, peptic ulcer disease and clotting disorder.
When stratified by race, the warfarin weekly maintenance dose was higher among African Americans (median 37.5 mg, mean 42.9 mg) than Caucasians (median 35.0 mg, mean 36.9 mg), a difference that was statistically significant (P ¼ 0.018). The effects of APOE genotype on warfarin maintenance dose, stratified by race, are shown in Table 3 . In the multivariable model adjusting for confounders, selected as described under Materials and methods, being an e4 carrier was associated with a statistically significant higher dose in African Americans (multivariable P ¼ 0.014) but not Caucasians (multivariable P ¼ 0.60, multivariable P value for interaction of genotype by race ¼ 0.20, Tables 3  and 4) . The three-level variable for APOE genotype showed the highest dose among those with e3/e4 or e4/e4 genotypes, the next highest among e3/e3 homozygotes and the lowest among those with e2/e3 or e2/e2 genotypes in both African Americans and Caucasians (Tables 3 and 4 and Figure 1) . However, the association was statistically significant only within the African American subgroup (multivariable P ¼ 0.012), not the Caucasian subgroup (multivariable P ¼ 0.81; multivariable P value for interaction ¼ 0.056).
There were only six patients with the e4/e4 genotype and they did not clearly require lower doses. However, the one Caucasian patient with e4/e4 was a VKORC1 1173C/T heterozygote, a genotype that is associated with low maintenance doses. In addition, one of the highest dose requirements was among one of the five African Americans with the e4/e4 genotype, 105 mg/week. The median dose among those with e2/e4 was 35.00 mg in both the few African Americans (n ¼ 7) and the few Caucasians (n ¼ 3) with this genotype, again consistent with the e3/e3 group.
APOE genotype was associated with higher maintenance doses among both African Americans and Caucasians who were homozygous wild type for CYP2C9, but this difference was only statistically significant among African Americans (Table 5) . Among subjects with a CYP2C9 variant, there were no statistically significant effects of APOE within either race, but there were very few subjects in these subgroups (Table  5) .
There was no apparent effect of APOE genotype on time to establishing a maintenance dose in the Caucasian or African American subgroups, when either e4 carrier status (P ¼ 0.84 for Caucasians, P ¼ 0.46 for African Americans) or the threelevel APOE genotype variable (P ¼ 0.27 for Caucasians, P ¼ 0.63 for African Americans) was considered.
Discussion
This study demonstrates that the APOE e4 allele is associated with a significantly higher warfarin maintenance dose requirement than other APOE alleles and that the relationship between different APOE genotype and dose requirement may follow the same pattern as the published relationships between APOE genotype and hepatic chylomicron clearance. 7, [9] [10] [11] [12] These findings were independent of CYP2C9 polymorphisms, the VKORC1 1173C/T variant, and numerous other factors that can alter warfarin dose requirements. The results were statistically significant among African Americans but not Caucasians; however, the e4 allele was less common among Caucasians, which could have limited our ability to detect an effect in this group.
Our findings could, at least in part, explain the higher warfarin dose requirement among African Americans that has previously been noted by others. 2 The e4 allele was associated with a higher maintenance dose of warfarin in African Americans, even after adjusting for the different frequencies of CYP2C9 and VKORC1 classes. Although the APOE genotype may have an effect on maintenance dose in Caucasians, the effect was less pronounced and not statistically significant. Regardless of any potential differences in magnitude of effect between African Americans and Caucasians, the fact that the APOE e4 allele is more common and the CYP2C9 and VKORC1 variants are much less common in African Americans than Caucasians suggests that different maintenance dose requirements could be driven by different prevalences of functionally relevant genetic polymorphisms between these two groups.
Hepatic clearance of chylomicrons, and therefore the vitamin K carried by chylomicrons, is at least partly dependent on APOE genotype, with e4 carriers having the most rapid clearance. 10 Thus, one hypothesis is that the APOE e4 variant facilitates a relatively high uptake of vitamin K by the liver and thus enhances the availability of vitamin K for carboxylation of clotting factors.
14 However, a contrasting hypothesis is that the greater hepatic clearance of vitamin K mandated by the APOE e4 variant does not translate into greater availability of vitamin K for the formation of functional coagulation factors and may, in fact, be associated with reduced availability because of greater catabolism of vitamin K. 13, 17 Our results support the former hypothesis.
Three prior studies have examined the effects of APOE genotype on warfarin dose requirement. Kohnke et al.
14 studied 183 Swedish patients (33.5% with one or two e4 alleles) and found that, among CYP2C9 wild-type homozygotes, those with the e4/e4 genotype required significantly higher warfarin maintenance doses than those with one or no e4 alleles. Although our study had too few e4/e4 patients to draw meaningful conclusions about this genotype class, our results are consistent with a similar effect of APOE genotype on maintenance dose, extending this finding to African Americans. A follow-up study by Kohnke et al. 15 failed to confirm the effect of APOE genotype on warfarin dose requirement in Italian patients; however, that cohort had only 20 (14%) e4 carriers and no e4/e4 homozygotes. Sconce et al. 16 found that the e4 allele was associated with lower doses in a Caucasian population, but, interestingly, e4 carriers had the highest plasma vitamin K concentrations, not the lowest as might be expected. [10] [11] [12] Clearly, the relationship between APOE genotype and warfarin dose requirements is complex; further study is needed to better understand the interactions between APOE and race, other genotypes, diet and vitamin K levels. In a retrospective study of different anticoagulants, acenocoumarol and phenprocoumon, Dutch Caucasian e4 carriers and homozygotes required a significantly lower mean dose of acenocoumarol, but not of phenprocoumon, relative to e3/e3 homozygotes. 13 Comparisons between our findings and those of this last study are necessarily limited, however, because of the use of different medications and a different definition of maintenance dose that may not represent steady-state requirements. Furthermore, the significant findings were limited to patients taking acenocoumarol and thus could represent the play of chance. With respect to warfarin specifically, our study is consistent with the prior Swedish study. 14 There are several strengths and potential limitations that must be considered in interpreting our results. Our study was prospective and specifically designed to test the hypothesis that APOE genotype would have an effect on warfarin maintenance dose. The prospective cohort design should prevent selection bias, a common concern in retrospective case-control studies. We also were able to control for numerous other factors that are known to alter warfarin response. However, we were only able to adjust for a single polymorphism in VKORC1. Although this polymorphism has been associated with lower warfarin dose in multiple studies and is just as informative as inferred haplotypes in Caucasians, 5, 18, 19 further assessment of other VKORC1 polymorphisms is needed. Due to our sample size, we also were limited in our ability to test for interactions by race, and interpretation of our findings must be tempered by the sample size and the possibility of erroneous findings. Our findings among e4/e4 patients is also not consistent with prior study, but we had very few patients with this genotype. Finally, our results may not generalize to other populations.
In conclusion, our study demonstrates that APOE genotype may affect warfarin maintenance dose requirements, particularly among African Americans, with higher doses needed by e4 allele carriers and lower doses needed by those with the e2/e2 and e2/e3 genotypes. These findings could at least partly explain the higher dose requirements noted previously in African Americans. Although the e4/e4 genotype was rare and not clearly associated with lower doses in this study, our study suggests that APOE genotype may play some role, along with other factors, in determining warfarin response and may explain some of the racial differences in warfarin dose requirements. 20 This study also excluded nine patients who were not self-reported Caucasian/white or African American/ black.
Materials and methods
Study population and data collection
Information on patient demographics, medical history, medication use, warfarin dose, diet and INR was obtained prospectively by trained study interviewers using standardized questionnaires. Genomic DNA was obtained from buccal swabs and was analyzed by facility staff blinded to patient characteristics or outcomes.
Genotyping DNA was extracted from buccal swab preparations using a method adapted from Richards et al. 21 Two sets of swabs were taken from each participant and used for validation of methods and quality control.
APOE genotypes (based on single nucleotide polymorphisms (SNPs) rs429358 and rs7412) were determined by the molecular genotyping and diagnostics facility at HUP using a standard method. 22 Briefly, polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) assays were performed in 50-ml reactions in PCR buffer that Indianapolis, IN, USA) . The 452-bp product was digested with 1.5 U AvaII (New England Biolabs) at 371C for 6 h. The products were separated on 3% agarose gels and visualized by ethidium bromide staining and UV illumination. For CYP2C9*3 (rs1057910), PCR amplifications were performed using 200 mM dNTPs, NW3 buffer, 2 mM MgCl 2 and 1.5 U Hotstar Taq Polymerase (Qiagen, Valencia, CA, USA) in a final volume of 25 ml. Genomic DNA (5 ml) and 0.2 pg of heteroduplex generator were coamplified in the presence of 200 nM of the forward primer (5 0 -CAGGAAGAGATTGAACGTGTG-3 0 ) and the reverse primer (5 0 -ACAAACTTACCTTGGGAATGAGA-3 0 ). The heteroduplexes and homoduplexes were separated on 12% polyacrylamide (2.6% crosslinking) minigels run at 150 V for 2 h and visualized using ethidium bromide staining and UV illumination. The CYP2C9*3 heteroduplex generator was validated against the Nsi I RFLP and gave the same results.
VKORC1 1173C/T (rs9934438) polymorphism was chosen because it has been demonstrated in several studies to be associated with lower dose requirements and is just as informative as inferred haplotypes in Caucasians. 5, 18, 19 The region containing the VKORC1 1173C/T (based on SNP rs9934438) variant was PCR amplified in 25-ml reactions in PCR buffer that contained 5 ml of genomic DNA, 200 nM forward (5 0 -AAGATGAAAAGCAGGGCCTAC-3 0 ) and reverse (5 0 -CCGAGAAAGGTGATTTCCAA-3 0 ) primers, 200 mM each dNTP, 1X PCR buffer (Qiagen), and 1 U HotStar Taq polymerase (Qiagen). Thermocycling conditions consisted of 951C for 5 min, followed by 45 cycles of 951C for 40 s, 591C for 50 s and 721C for 40 s, with a final extension step of 751C for 5 min. The 195-bp product was digested with 2 U StyI (New England Biolabs) at 371C for 6 h; the 1173T allele is cleaved to yield fragments of 125 and 70 bp. The products were separated on 12% polyacrylamide gels and visualized by ethidium bromide staining and UV illumination.
Outcomes
The primary outcome for the study was the maintenance dose of warfarin, determined using the standard definition as the dose that leads to a stable INR over three consecutive visits following initiation of the drug. 5 In addition, we examined the time required to reach the maintenance dose.
Statistical analysis
The demographic and clinical characteristics of subjects were compared by APOE genotype using w 2 or exact tests for categorical variables and Wilcoxon rank sum tests for continuous variables. The Hardy-Weinberg equilibrium test was used to assess whether genotype frequencies were in conformity with predictions based on allele frequencies. APOE genotype was categorized in two ways, first based on the presence or absence of any APOE e4 allele (e.g., e4/e4, e4/ e3 and e4/e2 versus non-e4), the 'e4 carrier' group. This was based on prior studies demonstrating that people with an e4 allele clear vitamin-K-rich lipoproteins from the circulation more efficiently and have lower plasma vitamin K concentrations than those who do not carry an APOE e4 allele 10, 11 and a prior study suggesting that the presence of the e4 allele is associated with higher warfarin dose requirements.
14 Second, we categorized APOE genotypes into three groups (the 'three-level APOE' variable), based on data suggesting that plasma vitamin K levels vary by these groups, with levels being highest among those with the e2/e2 or e2/e3 genotype, intermediate with e3/e3, and lowest with e4/e4 or e4/e3. 11 The e2/e4 genotype is rare 23 and vitamin K levels have not been studied in this class; therefore, the 10 e2/e4 patients were excluded a priori from analysis of the threelevel variable. 10, 12 The distribution for the warfarin maintenance dose was right-skewed, so transformations were performed to achieve approximate normality using the family of Box-Cox transformation 24 using a maximum likelihood criterion, 25 resulting in a square-root transformation on the maintenance dose. Linear regression analyses based on this transformation were then performed to test for differences in maintenance dose by APOE genotype and other potential confounders. Covariates that were associated with maintenance dose with a bivariate P value o0.2 were included in a multivariable linear regression model. Cox proportional hazards models were used to examine differences in the time to maintenance therapy by APOE genotype. For these analyses, patients who did not reach maintenance therapy were censored at their last follow-up visits. All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA) and Stata version 9 (StataCorp, College Station, TX, USA). The study was approved by the Institutional Review Boards at all participating hospitals, and all patients provided informed, written consent.
